Teitur Trophics gets funds

Country

Denmark

A 2020 spin-out company from Aarhus University in Denmark has raised €28 million in Series A financing from a syndicate of venture capitalists. Teitur Trophics ApS is building a pipeline of drugs directed against neurodegenerative diseases. Its first product, TT-P34, has reportedly shown brain-specific effects in animal models for Huntington’s disease, Parkinson’s disease and frontotemporal dementia.